RHOEN-KLINIKUM (ETR:RHK) target price raised to 31.00EUR, reported today by Commerzbank AG
- Updated: September 19, 2016
RHOEN-KLINIKUM (ETR:RHK) had its price target upped to 31EUR by Commerzbank AG in an issued report issued 9/19/2016. The updated target price indicates a potential upside of 0.13% from the bussiness’ previous stock close price.
Previously on 8/31/2016, Commerzbank AG reported about RHOEN-KLINIKUM(ETR:RHK) bumped the target price from 0.00EUR to 31.00EUR. At the time, this indicated a possible upside of 0.17%.
Yesterday RHOEN-KLINIKUM (ETR:RHK) traded 0.00% even at 27.46EUR. RHK’s 50-day average is 0.00EUR and its two hundred day moving average is 0.00EUR. The last close is up 0.00% from the 200-day moving average, compared to the S&P 500 which has fallen -0.01% over the same time. 0 shares of RHK traded hands, from ann avg. trading volume of 0.
Recent Performance Graph:
With a total market value of 0.0 EUR, RHOEN-KLINIKUM has a PE of 0 with a 52 week low of 0.00EUR and a one-year high of 0.00EUR.
General Information About RHOEN-KLINIKUM (ETR:RHK)
Rhoen Klinikum AG is a Germany-based provider of health care services. It is primarily engaged in building, acquiring and operating privately owned hospitals. The Company’s portfolio comprises basic and standard care, intermediate care, maximum care, specialist care, medical care centers (MVZ) at hospitals, portal clinics, university hospitals and academic teaching hospitals. These hospitals offer treatment in several specialist fields, including psychiatry, anesthesiology, dermatology, ophthalmology, various types of surgery, women’s medicine and obstetrics, geriatrics, neurology, rehabilitation, urology and internal medicine, among others. The Company operated a number of hospitals and medical care centers. In addition to the hospitals in Bad Berka, Frankfurt, Hildesheim, Karlsruhe, Munich, Pforzheim and Wiesbaden, among others, it has MVZ companies located in Germany, and as well as two research and education companies and service companies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.